, SCYNEXIS to Participate in the Cantor Antibiotics Summit, WorldNews | Travel Wire News

SCYNEXIS to Participate in the Cantor Antibiotics Summit

JERSEY CITY, N.J., Jan. 11, 2018 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in a panel entitled “Novel Ways to Treat and/or Address Infections” at the Cantor Antibiotics Summit at the Omni Berkshire Hotel, New York, on Wednesday, January 17, 2018 at 12:15 p.m. ET.

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company’s lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

GOT NEWS? click here

possible to reach millions worldwide
Google News, Bing News, Yahoo News, 200+ publications


Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
[email protected]

Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
[email protected]  

, SCYNEXIS to Participate in the Cantor Antibiotics Summit, WorldNews | Travel Wire News View original content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-the-cantor-antibiotics-summit-300581688.html


Related Links